Skip to main content

Antibe Therapeutics Inc(ATE-T)
TSX

Today's Change
Real-Time Last Update

Stocks in play: Antibe Therapeutics Inc

Baystreet - Wed Oct 18, 2023

Announced the initiation of the pharmacokinetic/pharmacodynamic study of otenaproxesul’s faster-absorbing formulation for acute pain. The study is designed to inform the doses and confirm safety in preparation for the Phase II trial, on track to launch in calendar Q1 2024. Antibe Therapeutics Inc shares T.ATE are trading unchanged at $0.45.

Provided Content: Content provided by Baystreet. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe